That should ensure adequate supply for coming influenza season, officials say
FRIDAY, Sept. 28 (HealthDay News) -- With flu season fast approaching, U.S. health officials announced Friday the approval of a new vaccine intended for people 18 and older.
The vaccine, called Afluria, is designed to protect adults from influenza viruses type A and type B.
"Today's action is important, because it brings to six the number of companies licensed to supply flu vaccine in the United States," Dr. Jesse L. Goodman, director of the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research, said during an afternoon teleconference.
Goodman noted that in 2000, there were only three manufacturers of flu vaccine for the United States. In 2004, one manufacturer had problems with the sterility of its British production facility, which caused a severe shortage of vaccine in the United States.
Since then, the FDA has been looking for other vaccine manufacturers to fill the gap and ensure that even if there were a problem with one manufacturer, there would still be an adequate supply, Goodman said.
Afluria was approved using the FDA's accelerated approval process, said Norman Baylor, director of FDA's office of vaccines research and review.
"This process allows the agency to approve products for serious or life-threatening diseases based on early evidence of the product's effectiveness," Baylor said at the teleconference. "This accelerated approval process can reduce the time for needed medical product to become available to the public."
Afluria is made by CSL Limited of Parkville, Australia. The company is expected to supply about 2 million doses of the vaccine to the United States market this year.
The approval means there will be an estimated 132 million doses of flu vaccine for the 2007-2008 influenza season. That's 10 million doses more than last year, officia
All rights reserved